159 related articles for article (PubMed ID: 37408209)
1. Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity.
Bolf EL; Beadnell TC; Rose MM; D'Alessandro A; Nemkov T; Hansen KC; Schweppe RE
Cells; 2023 May; 12(10):. PubMed ID: 37408209
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
[TBL] [Abstract][Full Text] [Related]
3. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.
Beadnell TC; Mishall KM; Zhou Q; Riffert SM; Wuensch KE; Kessler BE; Corpuz ML; Jing X; Kim J; Wang G; Tan AC; Schweppe RE
Mol Cancer Ther; 2016 Aug; 15(8):1952-63. PubMed ID: 27222538
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.
Sun Y; Lin X; Aske JC; Ye P; Williams C; Abramovitz M; Leyland-Jones BR
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1241-1256. PubMed ID: 31541266
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
Teng Y; Cai Y; Pi W; Gao L; Shay C
J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
[TBL] [Abstract][Full Text] [Related]
6. Src inhibitors in suppression of papillary thyroid carcinoma growth.
Henderson YC; Toro-Serra R; Chen Y; Ryu J; Frederick MJ; Zhou G; Gallick GE; Lai SY; Clayman GL
Head Neck; 2014 Mar; 36(3):375-84. PubMed ID: 23729178
[TBL] [Abstract][Full Text] [Related]
7. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
Chan CM; Jing X; Pike LA; Zhou Q; Lim DJ; Sams SB; Lund GS; Sharma V; Haugen BR; Schweppe RE
Clin Cancer Res; 2012 Jul; 18(13):3580-91. PubMed ID: 22586301
[TBL] [Abstract][Full Text] [Related]
8. Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis.
Kessler BE; Mishall KM; Kellett MD; Clark EG; Pugazhenthi U; Pozdeyev N; Kim J; Tan AC; Schweppe RE
Oncogene; 2019 Apr; 38(14):2565-2579. PubMed ID: 30531837
[TBL] [Abstract][Full Text] [Related]
9. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
Nagaraj NS; Smith JJ; Revetta F; Washington MK; Merchant NB
Mol Cancer Ther; 2010 Aug; 9(8):2322-32. PubMed ID: 20682659
[TBL] [Abstract][Full Text] [Related]
10. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
McKnight BN; Viola-Villegas NT
Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
[TBL] [Abstract][Full Text] [Related]
11. A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.
Duska LR; Petroni GR; Lothamer H; Faust W; Beumer JH; Christner SM; Mills AM; Fracasso PM; Parsons SJ
Cancer Chemother Pharmacol; 2019 Mar; 83(3):473-482. PubMed ID: 30535536
[TBL] [Abstract][Full Text] [Related]
12. Src-family kinase inhibitors block early steps of caveolin-1-enhanced lung metastasis by melanoma cells.
Ortiz R; Díaz J; Díaz-Valdivia N; Martínez S; Simón L; Contreras P; Lobos-González L; Guerrero S; Leyton L; Quest AFG
Biochem Pharmacol; 2020 Jul; 177():113941. PubMed ID: 32240650
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer.
Mao L; Deng WW; Yu GT; Bu LL; Liu JF; Ma SR; Wu L; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2017 Mar; 140(5):1173-1185. PubMed ID: 27798955
[TBL] [Abstract][Full Text] [Related]
14. Src family kinases differentially influence glioma growth and motility.
Lewis-Tuffin LJ; Feathers R; Hari P; Durand N; Li Z; Rodriguez FJ; Bakken K; Carlson B; Schroeder M; Sarkaria JN; Anastasiadis PZ
Mol Oncol; 2015 Nov; 9(9):1783-98. PubMed ID: 26105207
[TBL] [Abstract][Full Text] [Related]
15. Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy.
Sinnett-Smith J; Anwar T; Reed EF; Teper Y; Eibl G; Rozengurt E
Mol Cancer Ther; 2022 Nov; 21(11):1652-1662. PubMed ID: 35999654
[TBL] [Abstract][Full Text] [Related]
16. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Serrels A; Macpherson IR; Evans TR; Lee FY; Clark EA; Sansom OJ; Ashton GH; Frame MC; Brunton VG
Mol Cancer Ther; 2006 Dec; 5(12):3014-22. PubMed ID: 17148760
[TBL] [Abstract][Full Text] [Related]
17. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.
Lue HW; Cole B; Rao SA; Podolak J; Van Gaest A; King C; Eide CA; Wilmot B; Xue C; Spellman PT; Heiser LM; Tyner JW; Thomas GV
Oncotarget; 2015 Dec; 6(42):44675-87. PubMed ID: 26625308
[TBL] [Abstract][Full Text] [Related]
18. A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma.
Sun J; Wang X; Tang B; Liu H; Zhang M; Wang Y; Ping F; Ding J; Shen A; Geng M
Theranostics; 2018; 8(12):3256-3267. PubMed ID: 29930727
[TBL] [Abstract][Full Text] [Related]
19. SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
Larsen SL; Laenkholm AV; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
PLoS One; 2015; 10(2):e0118346. PubMed ID: 25706943
[TBL] [Abstract][Full Text] [Related]
20. Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo.
Fan F; Ghosh S; Powell R; Roszik J; Park Y; Sobieski M; Sorokin A; Stephan C; Kopetz S; Ellis LM; Bhattacharya R
PLoS One; 2023; 18(3):e0281063. PubMed ID: 36952536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
